ArticleNature communications2018
Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Design Strategies for Developing Chiral Macrocyclic Chelators as a Diagnostic Tool.Accounts of chemical research · 2026Article
- Absolute Temperature Mapping Using Chiral Terbium Parashift Complexes for MRI Thermometry.Chemical & biomedical imaging · 2026Article
- Influences of Ring Sizes and Chiral Substituents on Macrocyclic Chelators for ImprovingJACS Au · 2026Article
- Review
- One-Step Assembly of α-Aryl-Substituted DOTAs as Superior and Universal Platforms for Multifunctional Theranostics.Angewandte Chemie (International ed. in English) · 2025Article
- Chiral Dysprosium-[7]Helicene Macrocycles Showing Record Single-Molecule Magnet Properties in the Lanthanide-Helicene Family.Journal of the American Chemical Society · 2025Article
- Article
- Design of Mn(1,4-DO2A) derivatives as stable and inert contrast agents for magnetic resonance imaging.Communications chemistry · 2025Article
- Chiral Strategy for Developing High-Performance Polymeric Gadolinium-Based MRI Contrast Agents for Vascular and Tumor Imaging.Chemical & biomedical imaging · 2025Article
- Chiral Switch of Gadopiclenol: New Standards in MRI Probes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ultra-inert lanthanide chelates as mass tags for multiplexed bioanalysis.Nature communications · 2024Article
- Synthesis of an Ethylenediaminetetraacetic Acid-like Ligand Based on Sucrose Scaffold and Complexation and Proton Relaxivity Studies of Its Gadolinium(III) Complex in Solution.Molecules (Basel, Switzerland) · 2024Article
- Decoration of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) with N-oxides increases the TChemistryOpen · 2024Article
- Development of Ln(III) Derivatives asInorganic chemistry · 2024Article
- Controlling the broadband enhanced light chirality with L-shaped dielectric metamaterials.Nature communications · 2024Article
- Design and synthesis of chiral DOTA-based MRI contrast agents with remarkable relaxivities.Communications chemistry · 2023Article
- Circularly polarized luminescence in the one-dimensional assembly of binaphtyl-based Yb(iii) single-molecule magnets.Journal of materials chemistry. C · 2023Article
- A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents.International journal of molecular sciences · 2023Article
- Rigidified and Hydrophilic DOTA-like Lanthanoid Ligands: Design, Synthesis, and Dynamic Properties.Inorganic chemistry · 2023Article
- Preparation of Patient Doses of [Nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite established clinical utilisation, there is an increasing need for safer, more inert gadolinium-based contrast agents, and for chelators that react rapidly with radiometals. Here we report the syntheses of a series of chiral DOTA chelators and their corresponding metal complexes and reveal properties that transcend the parent DOTA compound. We incorporated symmetrical chiral substituents around the tetraaza ring, imparting enhanced rigidity to the DOTA cavity, enabling control over the range of stereoisomers of the lanthanide complexes. The Gd chiral DOTA complexes are shown to be orders of magnitude more inert to Gd release than [GdDOTA]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.